DB
Therapeutic Areas
Senisca Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Oligonucleotide Senotherapeutics | Age-related diseases (unspecified) | Preclinical |
| Dermatology Programs | Skin health / age-related dermatological conditions | Preclinical |
Leadership Team at Senisca
DS
Dr Sarah Cole
Chief Executive Officer
PL
Professor Lorna Harries
Chief Scientific Officer, Co-founder
DT
Dr Tim Schmidt
Chief Development Officer
DA
Dr Adam Clauss
Head of Dermatology and Early Preclinical Development
DA
Dr Alice Ghidini
Head of Oligonucleotide Development